The last time volume was seen increasing in combination with a bullish crossover of the MACD indicator, Cord Blood America Inc. (OTCBB: CBAI) shares nearly doubled in price.
This time, the company’s ‘Clear Path to Profitability’ should give shares a much-deserved end-of-year boost. Or maybe we should say a boost much-deserved by patient shareholders.
Taken directly from the company’s release:
“Matthew Schissler, CEO, President and co-founder [Cord Blood America Inc. (OTCBB: CBAI)], said Cryo-Cell Mexico has more than 70,000 customers, operates in 32 states in Mexico with 13 affiliates, and has “an impressive, outstanding business model in partnering with hospitals. […] This acquisition is a game changer for our investors. The large gross profit influx should allow CBAI to operate off its own cash flow after one time acquisition and transitional costs have been normalized.”
With an influx of investment dollars towards research & development of stem cells, CBAI’s umbilical cord blood stem cell preservation business is a necessity.
Whether shares go on sale or are trading higher year-end, Cord Blood America Inc. (OTCBB: CBAI) should make for a nice holding heading into the New Year.